Cullinan/Taiho’s Zipalertinib Stands To Benefit From A Clear Market
The two companies announced positive topline results for the drug in pretreated EGFR exon 20 insertion mutation NSCLC, a market that Takeda vacated in 2023.
The two companies announced positive topline results for the drug in pretreated EGFR exon 20 insertion mutation NSCLC, a market that Takeda vacated in 2023.